OPUS-3

Lifitegrast data support dry eye efficacy over placebo dropsLifitegrast ophthalmic solution 0.05% (Xiidra, Shire) has demonstrated positive results for the treatment of the signs and symptoms of dry eye disease. Eye dryness scores for some patients have improved after two weeks of treatment with the topical drop.
New dry eye treatment demonstrates rapid onset symptomatic reliefResults from the Phase 3 OPUS-3 trial provide evidence confirming a benefit of lifitegrast ophthalmic solution 5.0% (Xiidra, Shire) for significantly improving dry eye disease-related symptoms, as measured by Eye Dryness Score.